Locations
Cambridge, MA, USA · Woburn, MA, USA · Cambridge, MA, USA
industry
Biotechnology
Size
11 - 50 employees
Stage
Series A
founded in
2015
At Zumutor, we are on a mission to develop novel immuno-onco-therapeutics that drive transformational improvements in cancer treatment through NK cell engagement. We leverage our proven proprietary antibody discovery - Inablr™ for fast track antibody discovery and development. Our team works in collaboration with a world-class scientific advisory board with expertise in immuno-oncology and clinical development. Our lead asset (ZM008) is a first-in-class antibody that targets certain receptors that block NK cell inhibitory signals and enable NK cell activation to generate a potent immune response. Development is on track for an IND filing by Q2 2022 and phase 1 clinical trial thereafter. We are headquartered in CIC Cambridge Campus, MA and R&D is carried out at an ISO certified lab in Bangalore, India.
Something looks off?